Clinical outcomes among patients stratified by the median numbers of cDCs or pDCs in the blood at 3 months posttransplant
| . | Greater than or equal to the median . | Less than the median . | P . |
|---|---|---|---|
| cDCs | ≥3/μL | <3/μL | |
| No. evaluated | 134 | 133 | |
| Incidence of posttransplant events | |||
| Cumulative grade 2-4 aGVHD at 6 mo | 45 (36-53) | 60 (52-68) | .01 |
| Cumulative grade 3-4 aGVHD at 6 mo | 12 (6-20) | 11 (4-20) | .89 |
| Cumulative cGVHD at 2 y | 60 (51-68) | 63 (55-71) | .7 |
| TRM at 2 y | 13 (8-19) | 23 (17-31) | .02 |
| Relapse at 2 y | 31 (23-39) | 31 (23-39) | .97 |
| Disease-free survival at 2 y | 57 (48-65) | 46 (37-54) | .07 |
| OS at 2 y for all patients | 68 (60-76) | 49 (40-57) | .001 |
| OS for BM recipients (N = 124 across strata) | 65 (52-76) | 45 (33-58) | .03 |
| OS for G-PB recipients (N = 143 across strata) | 65 (54-76) | 58 (46-69) | .35 |
| No. of deaths at 2 y | n = 69 | n = 90 | |
| Cause of death, n (%) | |||
| Primary disease | 46 (67) | 46 (51) | |
| Graft failure | 1 (1) | 2 (2) | |
| aGVHD | 6 (9) | 7 (8) | |
| cGVHD | 10 (14) | 29 (32) | |
| Infection | 2 (3) | 4 (4) | |
| Organ failure | 0 | 1 (1) | |
| New malignancy | 1 (1) | 0 | |
| TTP | 0 | 1 (1) | |
| IPN | 1 (1) | 0 | |
| GI bleed | 1 (1) | 0 | |
| Unknown | 1 (1) | 0 | |
| pDCs | ≥0.5/μL | <0.5/μL | |
| No. evaluated | 134 | 133 | |
| Cumulative grade 2-4 aGVHD at 6 mo | 42 (34-50) | 63 (55-71) | <.001 |
| Cumulative grade 3-4 aGVHD at 6 mo | 9 (3-16) | 14 (7-24) | .31 |
| Cumulative cGVHD at 2 y | 57 (49-66) | 65 (57-73) | .18 |
| TRM @ 2 y | 13 (8-19) | 23 (17-31) | .02 |
| Relapse at 2 y | 34 (26-42) | 28 (21-36) | .31 |
| Disease-free survival at 2 y | 54 (45-62) | 49 (40-57) | .43 |
| OS at 2 y | 63 (54-71) | 54 (46-63) | .15 |
| OS for BM patients (n = 124 across strata) | 63 (51-74) | 47 (35-59) | .03 |
| OS for G-PB patients (n = 143 across strata) | 61 (50-72) | 62 (50-73) | .92 |
| No. of deaths at 2 y | n = 77 | n = 82 | |
| Cause of death, n (%) | .57 | ||
| Primary disease | 51 (66) | 41 (50) | |
| Graft failure | 1 (1) | 2 (2) | |
| aGVHD | 4 (5) | 9 (11) | |
| cGVHD | 15 (19) | 24 (29) | |
| Infection | 3 (4) | 3 (4) | |
| Organ failure | 0 | 1 (1) | |
| New malignancy | 1 (1) | 0 | |
| TTP | 0 | 1 (1) | |
| IPN | 1 (1) | 0 | |
| GI bleed | 1 (1) | 0 | |
| Unknown | 0 | 1 (1) |
| . | Greater than or equal to the median . | Less than the median . | P . |
|---|---|---|---|
| cDCs | ≥3/μL | <3/μL | |
| No. evaluated | 134 | 133 | |
| Incidence of posttransplant events | |||
| Cumulative grade 2-4 aGVHD at 6 mo | 45 (36-53) | 60 (52-68) | .01 |
| Cumulative grade 3-4 aGVHD at 6 mo | 12 (6-20) | 11 (4-20) | .89 |
| Cumulative cGVHD at 2 y | 60 (51-68) | 63 (55-71) | .7 |
| TRM at 2 y | 13 (8-19) | 23 (17-31) | .02 |
| Relapse at 2 y | 31 (23-39) | 31 (23-39) | .97 |
| Disease-free survival at 2 y | 57 (48-65) | 46 (37-54) | .07 |
| OS at 2 y for all patients | 68 (60-76) | 49 (40-57) | .001 |
| OS for BM recipients (N = 124 across strata) | 65 (52-76) | 45 (33-58) | .03 |
| OS for G-PB recipients (N = 143 across strata) | 65 (54-76) | 58 (46-69) | .35 |
| No. of deaths at 2 y | n = 69 | n = 90 | |
| Cause of death, n (%) | |||
| Primary disease | 46 (67) | 46 (51) | |
| Graft failure | 1 (1) | 2 (2) | |
| aGVHD | 6 (9) | 7 (8) | |
| cGVHD | 10 (14) | 29 (32) | |
| Infection | 2 (3) | 4 (4) | |
| Organ failure | 0 | 1 (1) | |
| New malignancy | 1 (1) | 0 | |
| TTP | 0 | 1 (1) | |
| IPN | 1 (1) | 0 | |
| GI bleed | 1 (1) | 0 | |
| Unknown | 1 (1) | 0 | |
| pDCs | ≥0.5/μL | <0.5/μL | |
| No. evaluated | 134 | 133 | |
| Cumulative grade 2-4 aGVHD at 6 mo | 42 (34-50) | 63 (55-71) | <.001 |
| Cumulative grade 3-4 aGVHD at 6 mo | 9 (3-16) | 14 (7-24) | .31 |
| Cumulative cGVHD at 2 y | 57 (49-66) | 65 (57-73) | .18 |
| TRM @ 2 y | 13 (8-19) | 23 (17-31) | .02 |
| Relapse at 2 y | 34 (26-42) | 28 (21-36) | .31 |
| Disease-free survival at 2 y | 54 (45-62) | 49 (40-57) | .43 |
| OS at 2 y | 63 (54-71) | 54 (46-63) | .15 |
| OS for BM patients (n = 124 across strata) | 63 (51-74) | 47 (35-59) | .03 |
| OS for G-PB patients (n = 143 across strata) | 61 (50-72) | 62 (50-73) | .92 |
| No. of deaths at 2 y | n = 77 | n = 82 | |
| Cause of death, n (%) | .57 | ||
| Primary disease | 51 (66) | 41 (50) | |
| Graft failure | 1 (1) | 2 (2) | |
| aGVHD | 4 (5) | 9 (11) | |
| cGVHD | 15 (19) | 24 (29) | |
| Infection | 3 (4) | 3 (4) | |
| Organ failure | 0 | 1 (1) | |
| New malignancy | 1 (1) | 0 | |
| TTP | 0 | 1 (1) | |
| IPN | 1 (1) | 0 | |
| GI bleed | 1 (1) | 0 | |
| Unknown | 0 | 1 (1) |
The cumulative incidence of posttransplant complications, including death, relapse, TRM, aGVHD, and cGVHD, were determined among patients with greater than or fewer than the median number of cDCs or pDCs in the blood at 3 months posttransplant. Causes of death were assigned by a central data adjudication committee. Unless otherwise indicated, data are % (95% confidence interval).
GI, gastrointestinal; IPN, interstitial pneumonia; TTP, thrombotic thrombocytopenic purpura.